Brentuximab-induced hand-foot syndrome in a patient with cutaneous T-cell lymphoma

Brentuximab-induced hand-foot syndrome in a patient with cutaneous T-cell lymphoma

Bibliographic Details
Main Authors:	Guy Shaposhnik, MS, Sekwon Jang, MD, Jennifer A. DeSimone, MD
Format:	Article
Language:	English
Published:	Elsevier 2022-03-01
Series:	JAAD Case Reports
Subjects:	brentuximab vedotin cutaneous T-cell lymphoma drug eruption drug reaction hand-foot syndrome oncologic therapy
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352512622000066

Similar Items

Improvement of Cutaneous Anaplastic Large Cell Lymphoma by Brentuximab Vedotin Monotherapy
by: Takashi Onaka, et al.
Published: (2018-05-01)

Immediate Response to Brentuximab Vedotin in a Patient with Localized MF-LCT
by: Agnieszka Giza, et al.
Published: (2023-07-01)

Clinical Observation of 32 Cases of Malignant Lymphoma Treated with Brentuximab Vedotin Combined with Chemotherapy
by: CHAI Xiaofei, et al.
Published: (2023-03-01)

Brentuximab vedotin in the treatment of relapsed and refractory forms of Hodgkin lymphoma
by: E A Demina
Published: (2016-06-01)

Cutaneous Lymphoma and Antibody-Directed Therapies
by: Alvise Sernicola, et al.
Published: (2023-03-01)

Aggressive Primary Cutaneous Anaplastic T-Cell Lymphoma Successfully Treated with Autologous Stem Cell Transplant and Brentuximab Vedotin Consolidation: Case Report and Review of the Literature
by: Luca Guarnera, et al.
Published: (2022-03-01)

Advances in Immunotherapy for the Treatment of Cutaneous T-Cell Lymphoma
by: Pelcovits A, et al.
Published: (2023-09-01)

Potentials of brentuximab vedotin in the treatment of relapse/refractory cutaneous T-cell lymphomas: literature review and authors’ observation
by: L. G. Gorenkova, et al.
Published: (2019-07-01)

Brentuximab vedotin is the first target drug in the treatment of hodgkin lymphoma
by: G. S. Tumyan
Published: (2018-11-01)

Use of Brentuximab Vedotin in a Non-HIV Patient with Primary Effusion Lymphoma
by: Joana Ferra, et al.
Published: (2021-02-01)

Case Report: Brentuximab Vedotin Associated Acute Pancreatitis in a Pediatric Hodgkin Lymphoma Patient: Case Report and Literature Review
by: Ewelina Truszkowska, et al.
Published: (2022-08-01)

Cutaneous CD30 positive anaplastic large cell lymphoma mimicking breast carcinoma en cuirasse
by: Patrick McMullan, PhD, et al.
Published: (2023-10-01)

Successful brentuximab vedotin monotherapy against late relapse of classical Hodgkin lymphoma 6 years after first remission
by: Kana Nagashima, et al.
Published: (2020-03-01)

A case of metachronous peripheral T‐Cell non‐Hodgkin lymphoma following chemotherapy for Hodgkin disease successfully treated with brentuximab vedotin
by: Federico Meconi, et al.
Published: (2020-08-01)

Brentuximab vedotin in treating Chinese patients with lymphoma: A multicenter, real‐world study
by: Xudong Zhang, et al.
Published: (2023-12-01)

Safe prolonged use of brentuximab vedotin in a patient with Classical Hodgkin Lymphoma on hemodialysis
by: Aimee Schad, et al.
Published: (2023-09-01)

Cost-effectiveness of brentuximab vedotin in advanced stage Hodgkin’s lymphoma: a probabilistic analysis
by: A. J. N. Raymakers, et al.
Published: (2020-10-01)

Brentuximab vedotin therapy for cutaneous lesions in T-prolymphocytic leukemia: a case report
by: Jordan Senchak, et al.
Published: (2016-09-01)

Brentuximab vedotin resistance in classic Hodgkin's lymphoma and its therapeutic strategies: a review
by: Dayeeta Bera, et al.
Published: (2024-02-01)

The Role of Brentuximab Vedotin (BV) as Second-Line Treatment of Refractory Classical Hodgkin Lymphoma (cHL) in the Era of Pandemic COVID-19
by: Rajabto W, et al.
Published: (2022-06-01)

Cutaneous reactions with enfortumab vedotin: A case series and review of the literature
by: Allison S. Dobry, MD, et al.
Published: (2021-08-01)

Brentuximab Vedotin and Pembrolizumab Combination in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Single-Centre Retrospective Analysis
by: Fulvio Massaro, et al.
Published: (2022-02-01)

Pharmacoeconomic analysis of therapy with brentuximab vedotin, nivolumab and pembrolizumab in patients with relapsed Hodgkin’s lymphoma
by: N. A. Avxentyev, et al.
Published: (2020-12-01)

Brentuximab vedotin use in pediatric anaplastic large cell lymphoma
by: Jennifer E. Agrusa, et al.
Published: (2023-05-01)

Brentuximab vedotin in children and adolescents with Hodgkin’s lymphoma and anaplastic large cell lymphoma – literature review and own experience
by: N. V. Myakova, et al.
Published: (2016-03-01)

CCR4‐IL2 bispecific immunotoxin is more effective than brentuximab for targeted therapy of cutaneous T‐cell lymphoma in a mouse CTCL model
by: Zhaohui Wang, et al.
Published: (2023-07-01)

Cutaneous Anaplastic Large-Cell Lymphoma with Dramatic Response to Brentuximab Vedotin
by: Mustafa Şahin, et al.
Published: (2021-02-01)

The role of radiotherapy in patients with refractory Hodgkin's lymphoma after treatment with brentuximab vedotin and/or immune checkpoint inhibitors
by: Ruizhi Zhao, et al.
Published: (2024-03-01)

Brentuximab vedotin plus AVD followed by involved-node radiotherapy in a patient with classic Hodgkin lymphoma following gray zone lymphoma after autologous stem-cell transplantation failure
by: Norihiro Ueda, et al.
Published: (2023-12-01)

Therapeutic response in patients with CD30+ lymphomas to biological therapy
by: Cakić Jelena, et al.
Published: (2020-01-01)

Efficacy of brentuximab vedotin in patients with CD30-positive lymphoproliferative skin diseases: results of the first prospective study in the Russian Federation
by: Irena E. Belousova, et al.
Published: (2022-05-01)

Primary Cutaneous CD30-Positive Lymphoproliferative Disorders—Current Therapeutic Approaches with a Focus on Brentuximab Vedotin
by: Tomasz Stein, et al.
Published: (2024-01-01)

Evans Syndrome as a Possible Complication of Brentuximab Vedotin Therapy for Peripheral T Cell Lymphoma
by: Ruxandra Irimia, et al.
Published: (2023-03-01)

Brentuximab vedotin (Adcetris®) in therapy of system anaplastic large cell lymphoma. Case report
by: A. A. Semenova, et al.
Published: (2019-01-01)

Complete remission of Hodgkin’s lymphoma in a pediatric patient with TTN gene mutation treated with brentuximab vedotin combined chemotherapy without anthracyclines: A case report
by: Ying Li, et al.
Published: (2022-10-01)

Phase I clinical study of brentuximab vedotin (SGN-35) involving children with recurrent or refractory CD30-positive Hodgkin’s lymphoma or systemic anaplastic large cell lymphoma: rationale, design and methods of BV-HLALCL study: study protocol
by: Masahiro Sekimizu, et al.
Published: (2018-02-01)

Characterization of cutaneous adverse events to enfortumab vedotin: A retrospective case-control study
by: Ahmad Shahin, BS, et al.
Published: (2023-03-01)

Histopathological Markers for Target Therapies in Primary Cutaneous Lymphomas
by: Benedetta Sonego, et al.
Published: (2023-11-01)

Brentuximab-Induced Peripheral Neurotoxicity: A Multidisciplinary Approach to Manage an Emerging Challenge in Hodgkin Lymphoma Therapy
by: Roser Velasco, et al.
Published: (2021-12-01)

SUCCESSFUL USE OF BRENTUXIMAB VEDOTIN IN THE TREATMENT OF PROGRESSIVE PERIPHERAL UNSPECIFIED T-CELL LYMPHOMA IN AN ELDERLY FEMALE PATIENT
by: L. G. Gorenkova, et al.
Published: (2017-06-01)